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Twenty-nine laboratory-confirmed West Nile virus (WNV)
encephalitis patients were bled serially so that WNV-reactive
immunoglobulin (Ig) M activity could be determined. Of those
patients bled, 7 (60%) of 12 had anti-WNV IgM at approximate-
ly 500 days after onset. Clinicians should be cautious when
interpreting serologic results from early season WNV IgM-posi-
tive patients. 
I
n late summer and early fall of 1999, human West Nile virus
(WNV) infections were recognized for the first time in the
Western Hemisphere (1–6). Since its original introduction into
the New York City (NYC) area, WNV virus has caused disease
in humans, horses, and a wide variety of birds and other verte-
brates, spreading into the eastern two thirds of the United States
and also into Canada and the Caribbean Basin (7,8). The appar-
ent ability of WNV virus to be disseminated by infected birds
and to persist from year to year indicates that it will continue to
be a public health problem for the foreseeable future.
The detection of human cases of WNV encephalitis early
in the transmission season is a valuable tool to identify human
risk and seasonal virus activity. Diagnosis of WNV encephali-
tis is made by using an immunoglobulin (Ig) M antibody cap-
ture enzyme-linked immunosorbent assay (MAC-ELISA),
which demonstrates virus-reactive IgM in serum or cere-
brospinal fluid (CSF) from a person with a clinically compati-
ble illness (6,9–16). However, if WNV-reactive IgM is long
lasting (e.g., from one transmission season to the next), an early
season positive IgM test could result from either a recent or
past infection.
At least four previous studies, three with Japanese
encephalitis virus (JEV) (13,17,18) and one with WNV (19),
included evaluations of flavivirus-reactive IgM persistence.
Only one of the JEV studies evaluated the IgM activity in case-
patients >6 months after illness (17). Three of 41 JEV case-
patients demonstrated JEV-reactive IgM in serum >10 months
(300, 330, and 350 days) after onset. In the latter study of
human WNV infections, 50% of patients were still IgM posi-
tive after 2 months (19). We report the results of a longitudinal
study that followed laboratory-confirmed human WNV
encephalitis case-patients for up to 18 months to determine the
longevity of their serum WNV-reactive IgM.
The Study
Of the 55 surviving laboratory-confirmed case-patients
diagnosed with WNV encephalitis in the United States in 1999
(6), 29 agreed to participate in follow-up studies to assess their
recovery from disease and their WNV-reactive antibody levels.
Serum specimens were obtained and analyzed for the presence
of anti-WNV IgM and IgG antibodies by using MAC-ELISA
and indirect IgG ELISA as described (16,20). All cases were
originally laboratory confirmed by presence of WNV-reactive
IgM in acute cerebral spinal fluid specimens, identification of
WNV-reactive IgM in serum samples in the presence of WNV-
specific neutralizing antibodies, a >4-fold increase in WNV-
reactive neutralizing antibodies in serial serum specimens, or a
combination of these antibody activities.
For this analysis, all serum specimens from these case-
patients were considered independent samples, and multiple
specimens obtained at different times during the acute phase of
illness of the same patient were included in the temporal analy-
sis (Figure). MAC-ELISA results for acute-phase serum speci-
mens of the 33 remaining 1999 case-patients who were not fol-
lowed longitudinally were also included (Figure). When case-
patients became serologically negative for WNV-reactive IgM,
they were not subsequently resampled. Since the timing of the
sequential bleeds depended on the availability of the patients,
not all patients were sampled at all follow-up time intervals.
Results from the ELISA testing were expressed as a positive-
to-negative (P/N) ratio of observed A450nm (MAC-ELISA) or
A405nm (IgG ELISA) as described (16,20). In these tests, P/N
ratios >3.0 were considered positive, and P/N ratios >2.0 and
<3.0 were considered equivocal, requiring additional laborato-
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Figure. Scatterplot of anti–West Nile virus immunoglobulin M positive-
to-negative (P/N) values of individual serum specimens over time.
Dotted line represents P/N=3.0 cut-off.ry testing. The MAC-ELISA and IgG ELISA were run in trip-
licate for each specimen.
Scatter plot analysis of the IgM activity of all tested spec-
imens showed a typical WNV-reactive IgM response (Figure),
similar to that seen with human infections with that virus (19).
The IgM activity peaked within the first 20 days after onset. Of
the 29 case-patients followed for long-term antibody activity,
22 had serum specimens obtained approximately 200 days after
onset, 21 had serum specimens obtained 200–400 days after
onset, and 12 had serum specimens obtained >500 days after
onset (Table 1). Of the 22 specimens obtained approximately
200 days after onset, 14 (64%) were WNV-reactive IgM-posi-
tive (P/N values >3.0; range 3.0–10.8; average 6.3). An addi-
tional four specimens had equivocal results (P/N values from
2.0 to 2.99), which would require additional laboratory testing.
In total, 18 (82%) of 22 specimens had either positive or equiv-
ocal results at approximately 200 days after onset.
Of the 21 serum specimens obtained approximately
300–400 days after onset, 9 (43%) were WNV-reactive IgM-
positive (P/N values >3.0; range 3.1–6.5; average 4.0). An
additional four specimens had equivocal results (P/N values of
2.2, 2.2, 2.7, and 2.7), which would require additional labora-
tory testing. In total, 13 (62%) of 21 specimens had either pos-
itive or equivocal results at 300–400 days after onset.
Of the 12 serum specimens obtained approximately >500
days after onset, 5 (42%) were WNV-reactive IgM-positive
(P/N values>3.0; range 3.1–6.9; average 4.6). An additional
two specimens had equivocal results (P/N value 2.8), which
would require additional laboratory testing. In total, 7 (58%) of
12 specimens had either positive or equivocal results at approx-
imately 500 days after onset, with the latest positive specimen
having been drawn 525 days (17.5 months) after onset (P/N =
3.6).
As expected, most of the 29 case-patients had positive
WNV-reactive IgG results (P/N>3.0; range 3.2–8.8; average
6.3) in their last tested serum specimen. The one patient whose
P/N was <3.0 had a P/N of 2.8, which means that all specimens
would probably be considered WNV antibody-positive or at
least require additional laboratory testing. Although we did not
follow longitudinally the WNV-reactive IgM activity in the
CSF of these case-patients, the latest WNV-positive CSF spec-
imen ever submitted to Centers for Disease Control and
Prevention for diagnostic testing from a laboratory-confirmed
WNV human infection was obtained at 47 days after onset
(data not shown).
The percent of patients with detectable IgM antibodies at 9
months differed by age (Table 2), with 56% of those>65 years
of age being positive compared to 44% of those <65 years; the
difference was not statistically significant. No difference exist-
ed in the percentage positive at 1 year by sex or initial clinical
syndrome, with 18% of encephalitis patients being positive,
compared with 0% of meningitis patients. Patients with acute
IgM P/N ratios above the median appeared to be more likely to
remain positive over time than those with acute P/N ratios
below the median.
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Table 1. IgM and IgG P/N values of WNV virus patient serum samples 
by days after onset
a 
Case no.  Sample  Days after onset  WNV IgM  WNV IgG 
S1  12  14.3  2.0 
S2  197  3.9  7.8 
S3  340  3.5  8.2 
1  S4  498  2.8  nd
a 
S1  97  12.0  5.3 
2  S2  378  3.2  nd 
S1  72  8.2  5.0 
S2  186  7.3  7.0 
3  S3  388  1.0  nd 
S1  27  17.3  3.4 
4  S2  311  2.7  6.4 
S1  31  11.0  5.5 
S2  215  2.8  7.9 
5  S3  374  1.3  nd 
S1  39  5.9  2.8 
S2  173  7.6  3.9 
S3  332  3.5  4.3 
6  S4  502  3.1  nd 
S1  29  11.5  4.8 
S2  189  6.7  6.3 
S3  332  2.7  6.2 
7  S4  536  2.8  nd 
S1  3  3.3  6 
S2  15  10.7  5.0 
S3  30  nd  5.3 
S4  43  4.1  5.4 
S5  204  3.5  6.2 
S6  343  2.2  7.0 
8  S7  508  1.8  nd 
S1  21  13.6  4.4 
9  S2  199  1.7  3.2 
S1  55  9.0  3.7 
10  S2  189  10.8  6.0 
S1  17  24.6  5.2 
S2  255  3.6  4.3 
S3  336  3.1  7.5 
11  S4  512  6.9  nd 
S1  11  13.4  5.3 
S2  13  15.0  5.6 
S3  24  11.4  5.8 
12  S4  533  1.8  nd 
S1  8  16.7  3.4 
13  S2  202  4.2  nd 
S1  16  7.8  2.4 
S2  30  3.5  5.6 
14  S3  349  1.7  7.0 
S1  17  17.2  5.6 
S2  192  2.2  6.3 
15  S3  335  1.4  6.8 
S1  7  14.0  2.0 
S2  29  24.5  3.7 
16  S3  338  6.5  6.6 Conclusions
Identification of a recent human infection with WNV is a
important event that usually triggers public health alerts, mos-
quito control measures, and media attention. Because laborato-
ry tests for the presence of WNV-reactive IgM are used to iden-
tify such infections, they should be conducted properly, and the
test results must be interpreted accurately. Proper interpretation
criteria include considering clinical context (encephalitis or
meningitis), previous travel history, flaviviral vaccination his-
tory, and evidence of previous and current WNV activity in the
region. Cumulatively during 1999–2000, onset dates for human
WNV disease cases in the United States ranged from early July
to early December, roughly indicating a 5-month transmission
season and a 7-month nontransmission season (7,8). Based on
the serologic results presented here, approximately 50% of per-
sons with an acute WNV infection of the central nervous sys-
tem would be expected to have persistent IgM antibody for >8
months. The presence of WNV-reactive IgM in serum alone,
therefore, is not necessarily diagnostic of an acute WNV infec-
tion. These IgM results with human WNV infections concur
with the previously published results of human JEV infections
and suggest that the temporal characteristics of the human anti-
body response to related neurotropic flaviviruses (e.g., WNV,
JEV, St. Louis encephalitis virus, and Murray Valley encephali-
tis virus) are similar (17).
Given the low incidence of indigenously acquired neu-
rotropic flavivirus infections in the United States, however, this
similarity would seem to be more of a theoretical concern than
a practical one (i.e., the chance of a person in the United States
acquiring WNVencephalitis or meningitis during a given trans-
mission season, maintaining a significant level of virus-specif-
ic IgM activity over the ensuing 8–12 months, and then again
developing a viral encephalitis, meningitis, or being re-exposed
to WNV during the subsequent transmission season is highly
unlikely). Therefore, when evaluating a patient with acute viral
encephalitis acquired in the United States, a positive serum test
for IgM antibody to WNV would be expected to have a high
predictive value, particularly during July to December, and
especially when additional evidence exists of current epizootic
or epidemic WNV activity in the area.
Nevertheless, especially in areas where WNV is known to
have circulated previously or has an extended transmission sea-
son (e.g., Florida), suspected cases of acute WNV disease of
the central nervous system should be confirmed by the demon-
stration of WNV-reactive IgM in CSF, the development of
WNV-specific IgG antibody in convalescent-phase serum (ide-
ally, by demonstrating a fourfold change in neutralizing anti-
body titer between the acute and convalescent phases), or both.
We have determined empirically that the cross-reactivity of the
WNV-reactive IgM appears to be less than that of Saint Louis
encephalitis virus-reactive human IgM; therefore, conducting
concurrent tests with the other indigenous neurotropic fla-
viviruses, which now coexist with WNV in some parts of the
United States (21), is also important. 
The observed apparent-to-inapparent WNV infection ratio
in the United States is approximately 1:140, which indicates
that a large group of persons with subclinical WNV infections
exist (22). While the serologic results presented here are for
patients with neuroinvasive WNV disease and may not be gen-
eralizable to patients with clinically mild or inapparent WNV
infection, the possibility exists that many mild (and probably
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Table 1 ( continued). IgM and IgG P/N values of WNV virus patient 
serum samples by days after onset
a 
Case no.  Sample  Days after onset  WNV IgM  WNV IgG 
S1  79  8.5  5.7 
S2  200  7.5  4.5 
S3  337  4.1  4.6 
17  S4  525  3.6  nd 
S1  50  7.3  4.8 
S2  55  6.6  3.3 
S3  68  4.4  nd 
S4  207  2.9  7.3 
18  S5  505  1.3  nd 
S1  4  10.5  4.0 
S2  14  7.3  4.1 
19  S3  355  1.3  nd 
S1  29  18.0  3.1 
S2  257  3  8.8 
20  S3  373  1.7  nd 
S1  1  10.1  3.6 
S2  7  9.2  3.5 
21  S3  180  1.2  2.8 
S1  6  25.7  2.4 
S2  185  9.1  6.9 
S3  319  3.4  8.2 
22  S4  497  4.2  Nd 
S1  25  12.3  5.5 
S2  204  3.0  7.2 
23  S3  529  1.7  nd 
S1  4  11.4  3.2 
S2  8  9.1  3.5 
S3  14  19.6  2.7 
S4  212  2.9  6.3 
24  S5  361  1.9  nd 
S1  9  9.1  4.8 
S2  34  6.7  5.2 
25  S3  223  1.5  5.0 
S1  10  14.8  2.3 
S2  22  16.1  3.7 
S3  191  10.4  3.2 
S4  387  3.4  nd 
26  S5  514  5.2  nd 
S1  3  11.1  3.7 
S2  180  7.8  5.8 
S3  322  5.1  8.3 
27  S4  518  2.4  nd 
S1  26  4.9  6.0 
S2  32  4.3  5.6 
28  S3  298  2.2  nd 
S1  217  2.4  6.7 
29  S2  351  1.8  8.1 
a Ig, immunoglobulin; P/N, positive-to-negative; WNV, West Nile virus; nd, not done. undiagnosed) infections occur and further emphasizes the need
for careful laboratory assessment before a diagnosis of acute
WNV infection.
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Table 2. Percentage of persons with IgM-positive serology by months after onset  
  No. WNV IgM positive/total (%) 
  Acute (n=27)  3 months (n=15)  6 months (n=23)  9 months (n=23)  12 months (n=18) 
Age           
<65 yrs  9/9 (100)  6/6 (100)  6/9 (67)  4/8 (50)  0/5 (0) 
+65 yrs  18/18 (100)  9/9 (100)  9/14 (64)  5/15 (33)  2/13 (15) 
Sex           
Male  13/13 (100)  8/8 (100)  8/11 (73)  3/10 (30)  1/9 (11) 
Female  14/14 (100)  7/7 (100)  7/12 (58)  6/13 (46)  1/9 (11) 
Clinical syndrome           
Encephalitis  16/16 (100)  8/8 (100)  8/13 (62)  5/13 (39)  2/11 (18) 
Meningitis  11/11 (100)  7/7 (100)  7/10 (70)  4/10 (40)  0/7 (0) 
Baseline IgM
b           
<Median P/N  14/14 (100)  6/6 (100)  6/11 (55)  3/12 (25)  0/10 (0) 
>median P/N  13/13 (100)  9/9 (100)  9/12 (75)  6/11 (55)  2/8 (25) 
aWNV, West Nile virus; Ig, immunoglobulin; P/N, positive-to-negative; P/N ratio > 3.0. 
bMedian P/N = 11.4. 